Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00012298 · OUTCOME

Association Between In2B8 Scan and Positron Emission Tomography Scan Results (Phase I)

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2018-08-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
At week 12

What was measured

Explored using a contingency table and sensitivity and specificity will be calculated using 90% exact confidence intervals.

Analysis population: Not collected. Study team decision not to analyze this endpoint.

Groups in this outcome

Treatment (Radiolabeled Monoclonal Antibody Therapy)

Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV indium In 111 ibritumomab tiuxetan: Given IV oprelvekin: Given subcutaneously filgrastim: Given subcutaneously

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Radiolabeled Monoclonal Antibody Therapy)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Explored using a contingency table and sensitivity and specificity will be calculated using 90% exact confidence intervals.
groups
  1. description
    Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV indium In 111 ibritumomab tiuxetan: Given IV oprelvekin: Given subcutaneously filgrastim: Given subcutaneously
    id
    OG000
    title
    Treatment (Radiolabeled Monoclonal Antibody Therapy)
population Description
Not collected. Study team decision not to analyze this endpoint.
reporting Status
POSTED
time Frame
At week 12
title
Association Between In2B8 Scan and Positron Emission Tomography Scan Results (Phase I)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice